ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

3:00PM-4:30PM: Abstract Number: 1725

Exploring Risks of Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA) and Complications While Receiving Immune Checkpoint Inhibitors: Comparative Analysis

Abstracts: Immunological Complications of Medical Therapy

3:00PM-4:30PM: Abstract Number: 1710

Extl3 Involved in the Regulation of Endochondral Ossification in Axial SpA

Abstracts: SpA Including PsA – Basic Science

3:00PM-4:30PM: Abstract Number: 1748

Fracture Incidence Rates in Persons with Rheumatoid Arthritis by Disease Activity Level

Abstracts: RA – Diagnosis, Manifestations, & Outcomes III: Best Day (RA Subpopulations)

3:00PM-4:30PM: Abstract Number: 1746

Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinical Trials of Rheumatoid Arthritis

Abstracts: RA – Diagnosis, Manifestations, & Outcomes III: Best Day (RA Subpopulations)

3:00PM-4:30PM: Abstract Number: 1720

Herpes Zoster Risk Following Initiation of Immunosuppressive Therapy Among Adults with Rheumatic Disease

Abstracts: Health Services Research I

3:00PM-4:30PM: Abstract Number: 1735

High-Intensity Interval Training Outperforms Moderate Exercise in Aerobic Capacity for Recent-Onset Idiopathic Inflammatory Myopathies: A Randomized Controlled Trial

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science I

3:00PM-4:30PM: Abstract Number: 1728

Higher Oral Steroid Dose Is Associated with Worse Survival in Immune Checkpoint Inhibitor-Treated Rheumatoid Arthritis Patients with Metastatic Non-Small Cell Lung Cancer

Abstracts: Immunological Complications of Medical Therapy

3:00PM-4:30PM: Abstract Number: 1738

How Do Resident Physicians Choose a Career in Rheumatology?A Qualitative Analysis of Journey Maps

Abstracts: Professional Education

3:00PM-4:30PM: Abstract Number: 1711

Identification of Psoriatic Arthritis-related Pathways Using Multi-omics Data Integration

Abstracts: SpA Including PsA – Basic Science

3:00PM-4:30PM: Abstract Number: 1741

Implementing Strengths-Based, Positive Approaches Within Rheumatology Fellowship Training: A Realist Evaluation of Appreciative Inquiry-Based Interventions

Abstracts: Professional Education

3:00PM-4:30PM: Abstract Number: 1732

In Vitro Screening of siRNAs Designed to Knockdown Interferon Beta as a Novel Therapeutic Approach for Treatment of Adult and Juvenile Dermatomyositis

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science I

3:00PM-4:30PM: Abstract Number: 1722

Machine Learning-based Risk Stratification Tool to Predict Early Flare for Rheumatic and Musculoskeletal Diseases

Abstracts: Health Services Research I

3:00PM-4:30PM: Abstract Number: 1758

Minimal Spinal Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis over 2 Years of Bimekizumab Treatment: Results from a Phase 3 Open-Label Extension Study

Abstracts: SpA Including PsA – Treatment I

3:00PM-4:30PM: Abstract Number: 1715

Mortality Trends for Systemic Connective Tissue Diseases Across the United States from 1999 to 2020: A CDC-Wonder Database Analysis

Abstracts: Epidemiology & Public Health II

3:00PM-4:30PM: Abstract Number: 1742

Multi-Center Use of an Online Case-Based Simulation to Educate Pediatric Trainees on Musculoskeletal Complaints and High-Value Care

Abstracts: Professional Education

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].